Schonfeld Strategic Advisors’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,619
| Closed | -$244K | – | 2403 |
|
|
2025
Q4 | $244K | Sell |
3,619
-58,064
| -94% | -$3.91M | ﹤0.01% | 1641 |
|
|
2025
Q3 | $4.52M | Buy |
61,683
+866
| +1% | +$57.5K | 0.03% | 626 |
|
|
2025
Q2 | $3.16M | Buy |
60,817
+56,306
| +1,248% | +$3.2M | 0.02% | 759 |
|
|
2025
Q1 | $288K | Buy |
+4,511
| New | +$262K | ﹤0.01% | 1809 |
|
|
2024
Q4 | – | Sell |
-6,244
| Closed | -$357K | – | 2159 |
|
|
2024
Q3 | $357K | Sell |
6,244
-20,150
| -76% | -$1.16M | ﹤0.01% | 1570 |
|
|
2024
Q2 | $1.38M | Buy |
+26,394
| New | +$1.16M | 0.01% | 1065 |
|
|
2024
Q1 | – | Sell |
-34,502
| Closed | -$1.28M | – | 2196 |
|
|
2023
Q4 | $1.28M | Buy |
34,502
+27,949
| +427% | +$1.05M | 0.01% | 953 |
|
|
2023
Q3 | $250K | Buy |
+6,553
| New | +$268K | ﹤0.01% | 1356 |
|
|
2023
Q2 | – | Sell |
-27,993
| Closed | -$1.07M | – | 2285 |
|
|
2023
Q1 | $1.07M | Sell |
27,993
-302,807
| -92% | -$14.2M | 0.01% | 930 |
|
|
2022
Q4 | $18.8M | Sell |
330,800
-58,431
| -15% | -$2.99M | 0.16% | 180 |
|
|
2022
Q3 | $15.4M | Buy |
389,231
+95,593
| +33% | +$4.23M | 0.13% | 222 |
|
|
2022
Q2 | $12.9M | Buy |
293,638
+91,833
| +46% | +$3.97M | 0.13% | 218 |
|
|
2022
Q1 | $8.05M | Buy |
201,805
+16,037
| +9% | +$571K | 0.07% | 316 |
|
|
2021
Q4 | $7.47M | Buy |
185,768
+45,768
| +33% | +$1.71M | 0.07% | 354 |
|
|
2021
Q3 | $5.7M | Sell |
140,000
-105,600
| -43% | -$4.41M | 0.06% | 396 |
|
|
2021
Q2 | $11.2M | Buy |
245,600
+72,199
| +42% | +$3.2M | 0.12% | 259 |
|
|
2021
Q1 | $7.23M | Buy |
173,401
+131,663
| +315% | +$6.01M | 0.09% | 317 |
|
|
2020
Q4 | $1.78M | Sell |
41,738
-30,162
| -42% | -$1.08M | 0.02% | 627 |
|
|
2020
Q3 | $1.89M | Buy |
71,900
+11,509
| +19% | +$320K | 0.04% | 526 |
|
|
2020
Q2 | $1.62M | Buy |
60,391
+32,686
| +118% | +$737K | 0.04% | 467 |
|
|
2020
Q1 | $498K | Buy |
+27,705
| New | +$526K | 0.03% | 582 |
|
|
2019
Q3 | – | Sell |
-57,200
| Closed | -$983K | – | 1103 |
|
|
2019
Q2 | $983K | Sell |
57,200
-119,376
| -68% | -$1.93M | 0.03% | 445 |
|
|
2019
Q1 | $2.84M | Buy |
176,576
+153,576
| +668% | +$2.49M | 0.1% | 270 |
|
|
2018
Q4 | $336K | Buy |
+23,000
| New | +$367K | 0.01% | 792 |
|
|
2017
Q1 | – | Sell |
-70,428
| Closed | -$696K | – | 651 |
|
|
2016
Q4 | $696K | Buy |
+70,428
| New | +$771K | 0.09% | 282 |
|
Other funds holding HALO
VCM
VPM
Schonfeld Strategic Advisors's HALO Position: Q1 2026 in Review
Schonfeld Strategic Advisors sold out of Halozyme (HALO) in Q1 2026, closing a stake of 3,619 shares — an estimated $244K sold.
Schonfeld Strategic Advisors first reported a position in HALO in Q4 2016 and held it in 25 quarters. The position peaked at $18.8M in Q4 2022. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.
- Schonfeld Strategic Advisors reported no remaining Halozyme position as of Q1 2026 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 3,619 Halozyme shares in Q1 2026, an estimated $244K.
- Schonfeld Strategic Advisors first reported a position in Halozyme in Q4 2016 and held it in 25 quarters.
- Schonfeld Strategic Advisors's Halozyme position peaked at $18.8M in Q4 2022.
- 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.